Telo Genomics Corp

Telo Genomics Corp. is a molecular diagnostics company, which engages in the development of telomere analysis platforms in the industry. The company is headquartered in Toronto, Ontario. The company went IPO on 2012-02-15. These include liquid biopsies and related technologies in oncology and neurological diseases. The firm's lead application, TELO-MM is being developed to provide actionable information to medical professionals in the treatment of multiple myeloma, a form of blood cancer. Its clinical studies and product development design includes TeloView SMM, TeloView Test to Predict Patient Resistance to Treatment, development in collaboration with the Mayo Clinic and TeloView Test to monitor minimal residual disease in MM patients. The Company, by combining quantitative analysis of three-dimensional telomeres with molecular biology and artificial intelligence to recognize disease associated genetic instability, is developing products that improve day-to-day care for patients by serving the needs of pathologists, clinicians, academic researchers and drug developers.